FERMENTALG financials
FERMENTALG
9695007VNRQR6V5TMN85 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Cost of sales | €3.5M | €5.8M |
| Operating profit (EBIT) | -€11.8M | -€9.0M |
| Income tax expense | €0 | €0 |
| Profit for the year | -€14.1M | -€9.9M |
| — attributable to owners | -€14.1M | -€9.9M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | -€14.1M | -€9.7M |
| Per share | ||
| Basic EPS | €-0.32 | €-0.24 |
| Diluted EPS | €-0.32 | €-0.24 |
| Cash flow statement | ||
| Net cash from operating activities | -€8.7M | -€8.2M |
| Net cash from investing activities | -€1.8M | -€7.3M |
| Net cash from financing activities | €5.7M | €5.4M |
| Proceeds from borrowings | €6.4M | €1.5M |
| Repayments of borrowings | €750.0K | €525.0K |
| Balance sheet | ||
| Total assets | €50.2M | €57.5M |
| Non-current assets | €29.0M | €31.2M |
| Property, plant & equipment | €10.8M | €12.6M |
| Current assets | €21.3M | €26.3M |
| Inventories | €6.8M | €6.4M |
| Trade & other receivables | €1.1M | €1.3M |
| Cash & equivalents | €11.2M | €15.9M |
| Total equity | €30.8M | €42.0M |
| — attributable to owners | €30.8M | €42.0M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €15.3M | €11.0M |
| Current liabilities | €4.1M | €4.6M |
| Deferred tax liabilities | €0 | €0 |
| Derived metrics | ||
| Operating margin | -291.0% | -118.1% |
| Net margin | -348.6% | -129.1% |
| Return on equity | -45.9% | -23.5% |
| Cash conversion ratio | 0.61× | 0.83× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€395.0K | -€3.5M |
| Adjustments For Decrease Increase In Trade Account Receivable | €266.0K | €197.0K |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -€1.0M | €0 |
| Adjustments For Income Tax Expense | €0 | €0 |
| Adjustments For Increase Decrease In Trade Account Payable | -€93.0K | €355.0K |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €2.0K | -€66.0K |
| Adjustments For Sharebased Payments | €167.0K | €196.0K |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -€875.0K | -€459.0K |
| Cash Flows From Used In Increase Decrease In Current Borrowings | €0 | €0 |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€8.7M | -€6.6M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€14.1M | -€9.7M |
| Current Financial Liabilities | €1.0M | €831.0K |
| Current Tax Liabilities Current | €0 | €0 |
| Deferred Tax Assets | €0 | €0 |
| Equity and Liabilities | €50.2M | €57.5M |
| Expense From Sharebased Payment Transactions With Employees | €167.0K | €202.0K |
| Increase Decrease In Cash and Cash Equivalents | -€4.7M | -€10.1M |
| Increase Decrease In Working Capital | €7.0K | €1.6M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €167.0K | €196.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €347.0K | €0 |
| Increase Decrease Through Treasury Share Transactions | -€22.0K | -€94.0K |
| Intangible Assets Other Than Goodwill | €15.0M | €14.4M |
| Interest Income On Cash and Cash Equivalents | €294.0K | €17.0K |
| Interest Paid Classified As Financing Activities | €26.0K | €32.0K |
| Investment Accounted For Using Equity Method | €3.1M | €4.0M |
| Issue of Equity | €2.5M | €4.5M |
| Issued Capital | €2.1M | €1.7M |
| Noncurrent Financial Liabilities | €14.3M | €10.2M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €52.0K | €200.0K |
| Other Current Liabilities | €1.5M | €2.0M |
| Other Current Receivables | €2.2M | €2.6M |
| Other Finance Income Cost | -€1.3M | €39.0K |
| Other Noncurrent Assets | €54.0K | €301.0K |
| Other Noncurrent Liabilities | €681.0K | €538.0K |
| Other Revenue | €1.1M | €1.4M |
| Other Shortterm Provisions | €176.0K | €190.0K |
| Proceeds From Issuing Shares | €73.0K | €4.5M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €0 | €0 |
| Provisions For Employee Benefits | €282.0K | €253.0K |
| Purchase of Interests In Investments Accounted For Using Equity Method | €0 | €2.9M |
| Research and Development Expense | €4.4M | €4.8M |
| Reserve of Equity Component of Convertible Instruments | €473.0K | — |
| Revenue From Contracts With Customers | €4.1M | €7.6M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€875.0K | -€459.0K |
| Share Premium | €37.8M | €44.0M |
| Trade and Other Current Payables To Trade Suppliers | €1.4M | €1.5M |
Every line item above is a fact tagged in FERMENTALG's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.